Adicet Bio Inc Dossier - Source-backed chat

Adicet Bio Inc

ACETNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.40

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.14Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $66.8M

Enterprise Value $47.6M

Shares Outstanding 9.4M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Adicet Bio is a clinical-stage biotechnology company at a critical inflection point, transitioning its lead allogeneic gamma delta CAR-T cell therapy, prula-cel, into pivotal development for autoimmune diseases. The company's proprietary Vδ1 gamma delta T cell platform offers significant advantages over traditional autologous CAR-T therapies, including off-the-shelf availability, lower manufacturing complexity, and a favorable safety profile that enables outpatient dosing. Backed by a robust cash runway extending into the second half of 2027, Adicet is well-positioned to achieve multiple high-impact clinical and regulatory milestones throughout 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$34.83

High · most bullish analyst$100.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

Prula-cel's mid-2026 clinical update reveals safety concerns or underwhelming durability of response, delaying or halting the transition to a pivotal study. Regulatory delays push the ADI-212 IND filing into 2027, accelerating cash burn and forcing highly dilutive equity financing.

Base CaseCentral scenario

$18.0050%

Prula-cel delivers positive Phase 1 data in mid-2026, confirming its safety and therapeutic potential in LN and SLE. The company successfully aligns with the FDA on a pivotal trial design, initiating start-up activities in late 2026. ADI-212 IND is filed in Q3 2026, with Phase 1 enrollment beginning by year-end. Cash runway remains sufficient to support operations into 2H 2027.

Bull CaseUpside scenario

$27.0030%

Prula-cel's mid-2026 Phase 1 data demonstrates exceptional efficacy and a clean safety profile (no ICANS or severe CRS) in over 20 patients, prompting rapid FDA clearance for a pivotal Phase 2 trial. Outpatient dosing approval accelerates clinical adoption and commercial potential. Concurrently, ADI-212 enters the clinic smoothly in Q4 2026, validating the platform's utility in solid tumors (mCRPC).

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated allogeneic Vδ1 gamma delta T cell platform with off-the-shelf convenience.
FDA alignment on outpatient dosing for prula-cel, significantly reducing administration barriers.
Strong cash position of $137.6M providing runway into the second half of 2027.
Fast Track designations for prula-cel in multiple high-value autoimmune indications (LN, SLE, SSc).

Key Investment Risks

Clinical-stage risk with no approved products or commercial revenues.
High dependence on the clinical and regulatory success of a single lead asset (prula-cel).
Intense competition in the CAR-T and autoimmune cell therapy landscape.
Potential for future equity dilution to fund late-stage clinical trials.

Thesis Invalidation Triggers

Failure to obtain FDA clearance or reach alignment on the pivotal trial design for prula-cel in 2026.
Severe adverse safety events (e.g., high-grade ICANS or CRS) in the ongoing Phase 1 trial.
Inability to initiate Phase 1 enrollment for ADI-212 in mCRPC by late 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.